The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?

International Journal of Clinical Practice

Volumn 63, Issue SUPPL. 161, 2009, Pages 17-18

  Rich, J ^a   Hoeper, M M ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CALCIUM CHANNEL BLOCKING AGENT; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; TRK 100STP; UNCLASSIFIED DRUG; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; PROSTAGLANDIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE MARKER; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; EXERCISE TOLERANCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; JAW PAIN; LUNG ARTERY PRESSURE; MIXED CONNECTIVE TISSUE DISEASE; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SHORT SURVEY; SIDE EFFECT; SURVIVAL RATE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WALKING; DRUG DEVELOPMENT; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; DRUG DISCOVERY; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 58849159146     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01960.x     Document Type: Short Survey

References (8)

1. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation 2008 117 : 2966 8.
2. Macchia A, Marchioli R, Scarano M et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007 153 : 1037 47.
3. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992 327 : 76 81.
4. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy in primary pulmonary hypertension. N Engl J Med 1996 334 : 296 301.
5. Shapiro SM, Oudiz RJ, Cao T et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997 30 : 343 9.
6. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002 39 : 1496 502.
7. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003 41 : 2119 25.
8. Ikeda D, Tsujino I, Sakaue S et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007 71 : 1829 31.